drugset / Trial / NCT00004070
Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer
Phase 1/2
Completed
7 enrolled
Dana-Farber Cancer Institute
National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Participant with squamous cell cancer of head and neck are invited to participate in this study. In this study the investigators will be Inserting the gene for interleukin-12 into a person's cancer cells with the anticipation to make the body build an immune response to kill more tumor cells.
Timeline
- Start
- 1999-07
- Primary completion
- 2000-11
- Completion
- 2000-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | interleukin-12 | Protein / enzyme biologic | 3 mg/ml | — |
| Subject | interleukin-12 | Protein / enzyme biologic | 6 mg/ml | — |